Fol News

Tutti gli approfondimenti
Tutte le notizie

Caladrius Biosciences Inc(NASDAQ:CLBS)

  • Due nuove obbligazioni Societe Generale, in Euro e in Dollaro USA

    Societe Generale porta sul segmento Bond-X (EuroTLX) di Borsa Italiana due obbligazioni, una in EUR e una in USD, a tasso fisso decrescente con durata massima di 15 anni e possibilità di rimborso anticipato annuale a discrezione dell’Emittente.

    Per continuare a leggere visita questo LINK
Mi domando cosa dovrebbe succedere perché il prezzo del titolo possa risalire.
Io ci sto perdendo un sacco di soldi con sto titolo; è stato davvero un pessimo investimento.
Certo che il Vaticano che ci ha messo un milione di euro, è messo peggio di me.
 
2.4738+0.1038 (+4.38%)
As of 9:51AM EST. Market open.

Certo che questo titolo è pazzesco; mentre tutto il mondo sta crollando, lui sale del 4,38%.
 
Caladrius Biosciences to Receive $10.9 Million of Non-Dilutive Capital Through New Jersey Technology Business Tax Certificate Transfer Program

BASKING RIDGE, N.J. (April 22, 2020) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), today announced that it has finalized an agreement to sell $10.9 million in New Jersey net operating losses (“NJ NOLs”) to a qualifying and approved buyer pursuant to the New Jersey Economic Development Authority (“NJEDA”)’s Technology Business Tax Certificate Transfer Program (the “Program”). The Program enables qualifying New Jersey-based biotechnology or technology companies to sell a percentage of their NJ NOLs and research and development tax credits to unrelated qualifying corporations.


“The ability to convert our NJ NOLs into non-dilutive capital is an exciting development for Caladrius, especially in these challenging financial times, and we appreciate the NJEDA’s commitment to supporting research and development for small New Jersey-based companies,” stated David J. Mazzo, Ph.D., President and Chief Executive Officer of Caladrius. “I am proud of our team’s efforts in this process and our continued success accessing non-dilutive funding from a variety of sources and am delighted that Caladrius is considered an integral part of New Jersey’s biopharmaceutical ecosystem. This infusion of capital will, among other things, support the continued advancement of our CD34+ technology-based clinical programs.”
 
Caladrius Biosciences Plans to Assess its CLBS119 Cell Therapy for Repair of COVID-19 Induced Lung Damage

FDA authorizes new IND for the study of CLBS119 in COVID-19 patients who experienced respiratory failure
BASKING RIDGE, N.J. (April 23, 2020) - Caladrius Biosciences Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease today announced that the U.S. Food and Drug Administration (“FDA”) has authorized its investigational new drug (“IND”) application for the study of CLBS119, a CD34+ cell therapy for repair of COVID-19 induced lung damage. The study will target patients with severe SARS-CoV-2 infection that required ventilatory support due to respiratory failure.

“We appreciate the FDA’s expeditious review and approval of the IND for CLBS119. Early reports indicate that many of the survivors of COVID-19 that required ventilatory support remain debilitated due to the lung injury sustained as a result of the virus. COVID-19 appears to damage the vasculature of the lungs and repair of that vasculature will be necessary for patients to achieve a full recovery. Although many therapies are targeting the SARS-CoV-2 virus itself or the reduction of severe inflammation during the acute phase of the illness, no therapy has been shown to repair COVID-19 induced lung damage,” said Douglas W. Losordo, M.D., FACC, FAHA, Chief Medical Officer at Caladrius. “CLBS119 offers the potential to repair the lung damage caused by COVID-19 and to address a serious unmet need for patients. In previous clinical trials and preclinical models, CD34+ cells consistently have shown evidence of vascular repair in multiple organs including models of severe lung inflammation. In the proposed trial, Caladrius plans to evaluate whether CD34+ cells can be used to effectively restore lung function in patients with severe SARS-CoV-2 infection that required ventilatory support due to respiratory failure.”
 
Dunque entreremo nel mondo Covid19, con una bella cura per chi ha avuto i polmoni danneggiati dai respiratori artificiali.
 
Caladrius Biosciences Announces $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
BASKING RIDGE, N.J. (April 23, 2020) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, cardiovascular disease, today announced that it has entered into definitive agreements with several institutional and accredited investors for the issuance and sale of an aggregate of 2,162,166 shares of its common stock, at a purchase price of $2.3125 per share, in a registered direct offering priced at-the-market under Nasdaq rules. Caladrius has also agreed to issue to the investors unregistered warrants to purchase up to an aggregate of 1,081,083 shares of common stock. The closing of the offering is expected to occur on or about April 27, 2020, subject to the satisfaction of customary closing conditions.

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

The warrants have an exercise price equal to $2.25 per share, are exercisable immediately upon issuance and will expire five and one-half years from the issuance date.

The Company currently intends to use the net proceeds from the offering for working capital and general corporate purposes, including the advancement of its CD34+ technology-based clinical programs.
 
Ciao Implacabile.:)

Forse la tua pazienza sta per essere ricompensata.
 
Miki & Varenne ha scritto:
Ma ne deve avere ..da vendere ... e non credo che sarà ripagato il suo loss a 62$?:eek: come fa as arrivare a 62 sta crosta...:bow::rolleyes:
Clicca per espandere...

Probabilmente ha fatto male i calcoli. Anni fa hanno fatto un revers/split di 1/10. Probabilmente le ha pagate meno.
 
Miki & Varenne ha scritto:
Ma scusa tu hai un pmc a 62$ ?:eek: Senza media...e quante ne hai giusto per curiosité?:mmmm:
Clicca per espandere...

Per fortuna non ne ho molte, ma attualmente la perdita è praticamente di tutto il capitale; di medie su pessimi titoli come questo non ne faccio.
Ai tempi lo acquistai perché lessi degli articoli molto interessanti e perché anche il Vaticano ci aveva investito 1 milione di $ per motivi etici (usano le cellule staminali adulte, senza quindi uccidere degli embrioni).
 
BASKING RIDGE, N.J., May 26, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, today announced that it has entered into definitive agreements with several institutional and accredited investors for the issuance and sale of an aggregate of 2,084,850 shares of its common stock, at a purchase price of $2.0625 per share, in a registered direct offering priced at-the-market under Nasdaq rules. Caladrius has also agreed to issue to the investors unregistered warrants to purchase up to an aggregate of 1,042,425 shares of common stock. The closing of the offering is expected to occur on or about May 28, 2020, subject to the satisfaction of customary closing conditions.


H.C. Wainwright & Co. is acting as the exclusive lead placement agent for the offering.

The warrants have an exercise price equal to $2.0625 per share, are exercisable immediately upon issuance and will expire five and one-half years from the issuance date.

The gross proceeds from the offering are expected to be approximately $4.3 million. The Company currently intends to use the net proceeds from the offering for working capital and general corporate purposes, including the advancement of its CD34+ technology-based clinical programs.
 
Devi accedere o registrarti per poter rispondere.
Indietro